Please assess the completion status of the following clinical trial:

Trial Title: Effects of Persistent Innate Immune Activation on Vaccine Efficacy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to receive three doses of an FDA-approved Hepatitis B vaccine~* Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies)~* Healthy volunteer without significant medical problems~Exclusion Criteria:~* Received any vaccine within a month prior to study vaccine~* Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen~* HIV positive~* For HCV-negative, healthy volunteers: History of HCV infection or positive HCV antibody test~* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study~* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol~* Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group)~* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications~* Any clinically significant acute or chronic medical condition requiring care by a primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation~* Unable to continue participation for 156 weeks~* History of previous Hepatitis B vaccination(s)~* Male or female \< 18 and \> 62 years of age~* Is pregnant or lactating~* History of Hepatitis B infection~* Clinical, laboratory, or biopsy evidence of cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Recombivax in HCV infected individuals (Type: ACTIVE_COMPARATOR): Recombivax vaccine administered IM to HCV-infected individuals
- Recombivax in healthy volunteers (Type: ACTIVE_COMPARATOR): Recombivax vaccine administered IM to healthy individuals

Based on this trial design, predict the completion outcome and termination type (if applicable).